Mandate

Vinge advises Medicover in connection with a directed share issue 

The board of directors of Medicover has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Medicover will raise proceeds of SEK 1.5 billion, before issue costs.

The share issue is directed to a large number of Nordic and international institutional investors, on the basis of an accelerated bookbuilding process carried out by SEB. 
 
Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2019, Medicover had revenue around €844 million and 28,800 employees.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Eléonore Friberg. 

Related

Vinge advises SBB in connection with its acquisition of shares in PPI against payment through a share issue in-kind

Vinge has advised SBB in connection with the agreement entered into with TRG, a Norwegian group of companies controlled by Kjell Inge Røkke and the principal owner of Aker ASA. Under the agreement, SBB has undertaken to carry out a share issue in-kind to TRG or, as applicable, Aker Property Group.
May 16, 2025

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025